Oral agents: First-line therapy for erectile dysfunction

European Urology, Supplement

Volumn 1, Issue 8, 2002, Pages 12-18

  Brock, Gerald ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Apomorphine; Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

APOMORPHINE; NITRATE; NITRIC OXIDE; SILDENAFIL; TADALAFIL; VARDENAFIL;

BACKACHE; COLOR VISION DEFECT; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; MYALGIA; NAUSEA; NOSE CONGESTION; OUTCOMES RESEARCH; PATIENT SATISFACTION; PHARMACODYNAMICS; PRIORITY JOURNAL; RHINITIS; SCORING SYSTEM; SEXUAL INTERCOURSE; SOMNOLENCE; SYNCOPE; VISUAL DISORDER; VOMITING;

EID: 0036871575     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00113-6     Document Type: Conference Paper

References (27)

1. Jardin A, Wagner G, Khoury S, Giuliano F, Goldstein I, Padma-Nathan H, editors. Recommendations of the First International Consultation on Erectile Dysfunction, co-sponsored by the World Health Organization (WHO). Plymouth: Health Publications Ltd., 2000, p. 709-26.
2. Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res 2001;13(3):S8-17.
3. Giuliano F, Allard J. Apomorphine SL (Uprima®): preclinical and clinical experiences learned from the first central nervous system-acting ED drug. Int J Impot Res 2002;14(1):S53-6.
4. Heaton JPW. Key issues from the clinical trials of apomorphine SL. World J Urol 2001;19:25-31.
5. Dula E, Bukofzer S, Perdok R, George M, Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39:558-64.
6. Mulhall JP, Bukofzer S, Edmonds AL, George M, Apomorphine SL Study Group. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction. Clin Ther 2001;23: 1260-71.
7. Bukofzer S, Livesey N. Safety and tolerability of apomorphine SL (Uprima®). Int J Impot Res 2001;13(3):S40-4.
8. Lincoln TM. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther 1989;41:479-502.
9. Sáenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2000;12(4): S34-8.
10. Ückert S, Kuthe A, Stief CG, Jonas U. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 2001;19:14-22.
11. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-48.
12. Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999;53:1011-8.
13. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404.
14. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E. Bandel T, the Vardenafil Study Group. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9.
15. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.
16. Sildenafil citrate (Viagra®) prescribing information. New York: Pfizer, 1999.
17. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49: 822-30.
18. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single dose. Eur Urol 2001;40:181-90.
19. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. Dose-normalized pharmacokinetics of tadalafil (IC351) administered as a single oral dose to healthy volunteers. Eur Urol Suppl 2002;1(1):152 [abstract 600].
20. Porst H, Rosen RC, Padma-Nathan H, Varanese L, Anglin G, Giuliano F. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J Urol 2002;167(4): 177 [abstract 709].
21. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetics of tadalafil (IC351). Int J Impot Res 2001;13(Suppl 4):S43 [abstract 120].
22. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51.
23. Hellstrom WJG, Overstreet JW, Shen WX, Yu A, Beasley CM, Watkins VS. Tadalafil has no effect on spennatogenesis or reproductive hormones. Manuscript in preparation.
24. Cheitlin MD, Hutter Jr AM, Brindis RG, Ganz P, Kaul S, Russell Jr RO, Zusman RM. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33:273-82.
25. Mittleman MA, Glasser DB, Orazem J, Collins M. Incidence of myocardial infarction and death in 53 clinical trials of Viagra® (sildenafil citrate). J Am Coll Cardiol 2000;35(Suppl A):302A [abstract 807-6].
26. Kloner RA, Watkins VS, Costigan TM, Bedding A, Mitchell MI, Emmick J. Cardiovascular profile of tadalafil, a new PDE5 inhibitor. J Urol 2002;167(4):176 [abstract 707].
27. Kloner RA, Mitchell MI, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Urol 2002;167(4):176-177 [abstract 708].